|
|
|
|
|
Sulfamethoxazole
drug data and news
Sulfamethoxazole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Sulfamethoxazole | ||
| Brand Names/Synonyms | A047; Apo-Sulfamethoxazole; Azo Gantanol; Azo-Gantanol; Bactrim; Bactrim Ds; Bactrim Pediatric; Bactrimel; Co-Trimoxazole; Cotrim; Cotrim D.S.; Eusaprim; Fectrim; Gamazole; Gantanol; Gantanol-Ds; MS 53; Metoxal; Radonil; SIM; Septra; Septra Ds; Septra Grape; Septran; Septrin; Simsinomin; Sinomin; Sulfamethalazole; Sulfamethoprim; Sulfamethoprim-Ds; Sulfamethoxazol; Sulfamethoxazole; Sulfamethoxazole & Trimethoprim; Sulfamethoxazole Trimethoprim; Sulfamethoxizole; Sulfamethylisoxazole; Sulfatrim; Sulfatrim Pediatric; Sulfatrim-Ds; Sulfatrim-Ss; Sulfisomezole; Sulmeprim; Sulmeprim Pediatric; Sulpha-Methoxizole; Sulphamethalazole; Sulphamethoxazol; Sulphamethoxazole; Sulphamethoxazole Bp 98; Sulphamethylisoxazole; Sulphisomezole; Trib; Trimeth/Sulfa; Trimetoprim-Sulfa; Urobak; Uroplus Ds; Uroplus Ss | ||
| Indication | For the treatment of bronchitis, prostatitis and urinary tract infections | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Sulfamethoxazole is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Sulfamethoxazole is normally given in combination with Trimethoprim (a dihydrofolate reductase inhibitor). Studies have shown that bacterial resistance develops more slowly with the combination of the two drugs than with either Trimethoprim or Sulfamethoxazole alone. | ||
| Mechanism Of Action | Sulfonamides inhibit bacterial dihydrofolate synthetase, causing interference in the conversion of p-aminobenzoic acid (PABA) into folic acid. As folic acid is a coenzyme responsible for the transport of one-carbon fragments from one molecule to another, it is an essential component of bacterial development. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, the immediate next step, and therefore act synergistically with the sulfonamides. | ||
| Sulfamethoxazole News (When available) |
Trimethoprim-Sulfamethoxazole Effective in Community-acquired MRSA ... May 10, 2006 BAY AREA Don't dump old medicine in toilet May 11, 2006 O1 isolation enhanced with antibiotic selection technique Apr 27, 2006 Reducing Warfarin Medication Interactions May 8, 2006 Boils and bats and bacteria... Oh my! Infectious disease ... May 2, 2006 View larger version (35K): May 3, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Anti-Infectives; Sulfonamides; ATC:J01EC01 | ||
| Absorption | Sulfamethoxazole is rapidly absorbed following oral administration. | ||
| Interactions |
Interactions for Sulfamethoxazole: In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported. It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when Gantanol is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. The presence of sulfamethoxazole may interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Gram negative and gram positive bacteria | ||
| Chemical IUPAC Name | 4-amino-N-(5-methyloxazol-3-yl)-benzenesulfonamide | ||
| Chemical Formula | C10H11N3O3S | ||
| Molecular Weight | 253.279 g/mol | ||
| Smiles String | CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N | ||
| Melting Point | 167 °C | ||
| Water Solubility | <0.1 g/100 mL | ||
| State | Solid | ||
| LogP/Hphobicity | 2.447 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | The metabolism of sulfamethoxazole occurs predominately by N4-acetylation, although the glucuronide conjugate has been identified. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 70% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Sulfamethoxazole.html http://www.rxlist.com/cgi/generic/trisulf.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00076 | ||
| CAS Registry Number | 723-46-6 | ||
| KEGG Compound ID | C07315 | ||
| PubChem ID | SID:156228 | ||
| PharmGKB ID | PA451544 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 421480 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |